DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR(R)

CUPERTINO, Calif., Jan. 17, 2020 -- (Healthcare Sales & Marketing Network) -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met yeste... Biopharmaceuticals, Drug Delivery, FDA DURECT, POSIMIR, bupivacaine

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045686

Source: HSMN NewsFeed - January 17, 2020 Category: Pharmaceuticals Source Type: news

More News: Anesthesia | Anesthesiology | Food and Drug Administration (FDA) | Marketing | Pharmaceuticals